Literature DB >> 15851432

Bisphosphonate treatment of bone disease.

N J Shaw1, N J Bishop.   

Abstract

In 1997 a review article on bisphosphonates in this journal identified 24 published articles relating to children at that time. Since then there has been a considerable increase in their use in clinical paediatric practice and research with there being nearly a further one hundred articles published at the time of writing.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15851432      PMCID： PMC1720410          DOI： 10.1136/adc.2003.036590

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  42 in total

1.  Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency.

Authors:  Clifford J Rosen; Sue Brown
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

2.  Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial.

Authors:  Richard C Henderson; Robert K Lark; Heidi H Kecskemethy; Freeman Miller; H Theodore Harcke; Steven J Bachrach
Journal:  J Pediatr       Date:  2002-11       Impact factor: 4.406

3.  Pamidronate treatment improves bone mineral density in children with Menkes disease.

Authors:  S Kanumakala; A Boneh; M Zacharin
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

4.  The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.

Authors:  Frank Rauch; Rose Travers; Horacio Plotkin; Francis H Glorieux
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

5.  Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.

Authors:  Frank Rauch; Horacio Plotkin; Leonid Zeitlin; Francis H Glorieux
Journal:  J Bone Miner Res       Date:  2003-04       Impact factor: 6.741

6.  Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism.

Authors:  Frank Rauch; Horacio Plotkin; Rose Travers; Leonid Zeitlin; Francis H Glorieux
Journal:  J Clin Endocrinol Metab       Date:  2003-03       Impact factor: 5.958

7.  Use of disodium pamidronate in children with hypercalcemia awaiting liver transplantation.

Authors:  T M Attard; A Dhawan; S S Kaufman; D S Collier; A N Langnas
Journal:  Pediatr Transplant       Date:  1998-05

8.  Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.

Authors:  Margaret Zacharin; John Bateman
Journal:  J Pediatr Endocrinol Metab       Date:  2002-02       Impact factor: 1.634

Review 9.  Use of bisphosphonate therapy for osteoporosis in childhood and adolescence.

Authors:  J A Batch; J J Couper; C Rodda; C T Cowell; M Zacharin
Journal:  J Paediatr Child Health       Date:  2003-03       Impact factor: 1.954

10.  Impact of disordered puberty on bone density in beta-thalassaemia major.

Authors:  Basia K Bielinski; Phil J Darbyshire; Lynne Mathers; Nicola J Crabtree; Jeremy M W Kirk; Heather F Stirling; Nick J Shaw
Journal:  Br J Haematol       Date:  2003-01       Impact factor: 6.998
View more
  19 in total

1.  Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment.

Authors:  M L Bianchi; L Morandi; E Andreucci; S Vai; J Frasunkiewicz; R Cottafava
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

2.  Skeletal imaging effects of pamidronate therapy in osteosarcoma patients.

Authors:  Anita P Price; Sara J Abramson; Sinchun Hwang; Alexander Chou; Roger Bartolotta; Paul Meyers; Douglas S Katz
Journal:  Pediatr Radiol       Date:  2010-10-30

Review 3.  Vitamin D intoxication and therapy with alendronate (case report and review of literature).

Authors:  Zerrin Orbak; Hakan Doneray; Filiz Keskin; Ahmet Turgut; Handan Alp; Cahit Karakelleoglu
Journal:  Eur J Pediatr       Date:  2006-04-29       Impact factor: 3.183

4.  Oral Alendronate Treatment for Severe Polyostotic Fibrous Dysplasia due to McCune-Albright Syndrome in a Child: A Case Report.

Authors:  Ana Luiza Andrade Aragão; Ivani Novato Silva
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-21

5.  Can bisphosphonate treatment be stopped in a growing child with skeletal fragility?

Authors:  K A Ward; J E Adams; T J Freemont; M Z Mughal
Journal:  Osteoporos Int       Date:  2007-02-06       Impact factor: 4.507

Review 6.  Juvenile idiopathic arthritis: the paediatric perspective.

Authors:  Alison Jordan; Janet E McDonagh
Journal:  Pediatr Radiol       Date:  2006-05-11

Review 7.  Can bisphosphonates play a role in the treatment of children with chronic kidney disease?

Authors:  Dieter Haffner; Dagmar-Christiane Fischer
Journal:  Pediatr Nephrol       Date:  2011-01-27       Impact factor: 3.714

8.  Bisphosphonate-related osteonecrosis of the jaw: the Florence experience.

Authors:  Alberto Borgioli; Marco Duvina; Leila Brancato; Christian Viviani; Maria Luisa Brandi; Paolo Tonelli
Journal:  Clin Cases Miner Bone Metab       Date:  2007-01

9.  Fractures in myelomeningocele.

Authors:  Michael Akbar; Bjoern Bresch; Patric Raiss; Carl Hans Fürstenberg; Thomas Bruckner; Thorsten Seyler; Claus Carstens; Rainer Abel
Journal:  J Orthop Traumatol       Date:  2010-08-19

10.  Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.

Authors:  Samuel Gourion-Arsiquaud; Matthew R Allen; David B Burr; Deepak Vashishth; Simon Y Tang; Adele L Boskey
Journal:  Bone       Date:  2009-11-17       Impact factor: 4.398
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.